TD Private Client Wealth LLC Has $6.37 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

TD Private Client Wealth LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 34.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,687 shares of the pharmaceutical company’s stock after buying an additional 3,494 shares during the period. TD Private Client Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $6,366,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $25,000. Highline Wealth Partners LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $27,000. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. GHP Investment Advisors Inc. bought a new position in Vertex Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Stephens Consulting LLC acquired a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.0 %

Shares of VRTX opened at $469.22 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52-week low of $351.44 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The business’s fifty day moving average is $473.01 and its 200-day moving average is $475.84. The firm has a market cap of $120.84 billion, a price-to-earnings ratio of -235.79 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $3.67 earnings per share. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on VRTX. UBS Group boosted their price target on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Canaccord Genuity Group increased their price target on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. Scotiabank lifted their target price on Vertex Pharmaceuticals from $480.00 to $486.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Royal Bank of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Finally, Citigroup began coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $575.00 target price for the company. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $506.20.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.